{"success":true,"data":{"pressRelease":{"id":"164239","rtpr_id":"nPn87FhxQa-20261008","ticker":"TECH","exchange":"NASDAQ","all_tickers":["TECH"],"title":"Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development","author":"PR Newswire","published_at":"2026-10-08T12:00:07.851Z","article_body":"Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development\nPR Newswire\n\nMINNEAPOLIS, Oct. 8, 2026\n\n * Investment strengthens Bio-Techne's global GMP manufacturing infrastructure\nfor cell therapy applications\n * New Bristol facility expands GMP small molecule production capacity and\ncomplements recent investments in North America\n * Combined capabilities across Bristol, St. Paul and Minneapolis support\ncustomers from discovery through commercial manufacturing\nMINNEAPOLIS, Oct. 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:\nTECH), a global provider of life science tools, reagents and diagnostic\nproducts, today announced the opening of a new manufacturing facility for Good\nManufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom,\nfurther expanding the company's global capabilities to support the rapidly\ngrowing cell therapy market. The investment reflects Bio-Techne's commitment\nto helping therapy developers address one of the industry's most pressing\nchallenges: establishing scalable, reproducible manufacturing processes that\ncan support programs from early development through commercialization.\n\nThe purpose-built 10,000-square-foot Bristol facility features five ISO-8\nmultifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small\nmolecule manufacturing and product handling. Designed to meet the rigorous\nstandards required for advanced cell therapy manufacturing, the facility\nenhances Bio-Techne's ability to provide customers with high-quality GMP\nmaterials supported by robust quality systems and reliable global supply.\n\n\"As the cell therapy field continues to mature, success increasingly depends\non the ability to manufacture therapies consistently and at scale,\" said Kim\nKelderman, President and Chief Executive Officer of Bio-Techne. \"Our\ninvestment in Bristol demonstrates Bio-Techne's commitment to providing\ncustomers with the GMP materials, manufacturing expertise, and supply chain\nreliability needed to accelerate development and ultimately bring\ntransformative therapies to patients worldwide.\"\n\nThe Bristol expansion is the latest milestone in Bio-Techne's broader strategy\nto build a comprehensive manufacturing network supporting every stage of the\ncell therapy workflow. Together with the company's recombinant protein\nmanufacturing operations in Minneapolis, Minnesota, its extensive GMP\ncapabilities in St Paul, and its strategic relationship with Wilson Wolf\nCorporation, a leading manufacturer of cell culture devices including the\nwidely adopted G-Rex® platform, Bio-Techne offers an increasingly integrated\nportfolio of GMP proteins, GMP small molecules, GMP cell media, custom\nmanufacturing services, analytical solutions, and process development support.\nCollectively, these capabilities help customers transition seamlessly from\nresearch through clinical development and commercial production.\n\nCell therapy developers face mounting pressure to reduce variability,\nstandardize manufacturing processes, and scale production efficiently while\nmeeting evolving regulatory expectations. Bio-Techne addresses these\nchallenges through high-quality GMP materials, scalable manufacturing\nsolutions, and analytical technologies designed to improve consistency and\naccelerate development timelines. Recent industry discussions have\nincreasingly highlighted manufacturing scalability as a critical factor in\nenabling broader patient access to advanced therapies, reinforcing the\nimportance of investments such as the Bristol expansion.\n\n\"The opening of our Bristol facility represents more than additional\nmanufacturing capacity,\" said Will Geist, President of Bio-Techne's Protein\nSciences Segment. \"It strengthens Bio-Techne's ability to serve as a long-term\npartner for cell therapy innovators by providing the quality, scale, and\nglobal support necessary to navigate the journey from discovery to commercial\nsupply.\"\n\nThe Bristol facility is fully operational and is manufacturing GMP-grade small\nmolecules that support customers developing next-generation cell therapies\nworldwide.\n\nABOUT BIO-TECHNE\n\nBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company\nheadquartered in Minnesota, celebrating 50 years of empowering scientific and\ndiagnostic communities to reach better answers. The company provides\nhigh-quality reagents, analytical instruments, and precision diagnostics. Its\nportfolio is organized into three customer-focused brands: R&D Systems™,\nBio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the\nscientific journey from discovery to translational research to clinical\ndecision-making. Bio-Techne operates in 34 locations worldwide and employs\nmore than 3,000 people. In fiscal year 2025, the company generated over $1.2\nbillion in net sales. Its more than 500,000 products are used globally by\nacademic researchers, biopharmaceutical and biotechnology companies, and\nclinical diagnostic laboratories.\n\nFor more information on Bio-Techne and its brands, please visit\nwww.bio-techne.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789723-1&h=3730381129&u=https%3A%2F%2Fwww.bio-techne.com%2F&a=www.bio-techne.com)\n or follow the company on LinkedIn, X, or YouTube.\n\nMEDIA CONTACTS\n\nCorporate Communications\nmedia.relations@bio-techne.com (mailto:media.relations@bio-techne.com)\n\nDavid Clair, Vice President\nInvestor Relations\nIR@bio-techne.com (mailto:IR@bio-techne.com)\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/bio-techne-expands-global-gmp-manufacturing-network-with-new-bristol-facility-to-advance-scalable-cell-therapy-development-302900052.html\n(https://www.prnewswire.com/news-releases/bio-techne-expands-global-gmp-manufacturing-network-with-new-bristol-facility-to-advance-scalable-cell-therapy-development-302900052.html)\n\nSOURCE Bio-Techne Corporation\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS402613/Bio-Techne-Logo.jpg?id=OA2987796\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn87FhxQa-20261008","title":"Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development","author":"PR Newswire","ticker":"TECH","created":"2026-10-08T12:00:07.851Z","tickers":["TECH"],"exchange":"NASDAQ","article_body":"Bio-Techne Expands Global GMP Manufacturing Network with New Bristol Facility to Advance Scalable Cell Therapy Development\nPR Newswire\n\nMINNEAPOLIS, Oct. 8, 2026\n\n * Investment strengthens Bio-Techne's global GMP manufacturing infrastructure\nfor cell therapy applications\n * New Bristol facility expands GMP small molecule production capacity and\ncomplements recent investments in North America\n * Combined capabilities across Bristol, St. Paul and Minneapolis support\ncustomers from discovery through commercial manufacturing\nMINNEAPOLIS, Oct. 8, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:\nTECH), a global provider of life science tools, reagents and diagnostic\nproducts, today announced the opening of a new manufacturing facility for Good\nManufacturing Practice (GMP) grade small molecules in Bristol, United Kingdom,\nfurther expanding the company's global capabilities to support the rapidly\ngrowing cell therapy market. The investment reflects Bio-Techne's commitment\nto helping therapy developers address one of the industry's most pressing\nchallenges: establishing scalable, reproducible manufacturing processes that\ncan support programs from early development through commercialization.\n\nThe purpose-built 10,000-square-foot Bristol facility features five ISO-8\nmultifunctional cleanrooms and two ISO-7 cleanrooms dedicated to GMP small\nmolecule manufacturing and product handling. Designed to meet the rigorous\nstandards required for advanced cell therapy manufacturing, the facility\nenhances Bio-Techne's ability to provide customers with high-quality GMP\nmaterials supported by robust quality systems and reliable global supply.\n\n\"As the cell therapy field continues to mature, success increasingly depends\non the ability to manufacture therapies consistently and at scale,\" said Kim\nKelderman, President and Chief Executive Officer of Bio-Techne. \"Our\ninvestment in Bristol demonstrates Bio-Techne's commitment to providing\ncustomers with the GMP materials, manufacturing expertise, and supply chain\nreliability needed to accelerate development and ultimately bring\ntransformative therapies to patients worldwide.\"\n\nThe Bristol expansion is the latest milestone in Bio-Techne's broader strategy\nto build a comprehensive manufacturing network supporting every stage of the\ncell therapy workflow. Together with the company's recombinant protein\nmanufacturing operations in Minneapolis, Minnesota, its extensive GMP\ncapabilities in St Paul, and its strategic relationship with Wilson Wolf\nCorporation, a leading manufacturer of cell culture devices including the\nwidely adopted G-Rex® platform, Bio-Techne offers an increasingly integrated\nportfolio of GMP proteins, GMP small molecules, GMP cell media, custom\nmanufacturing services, analytical solutions, and process development support.\nCollectively, these capabilities help customers transition seamlessly from\nresearch through clinical development and commercial production.\n\nCell therapy developers face mounting pressure to reduce variability,\nstandardize manufacturing processes, and scale production efficiently while\nmeeting evolving regulatory expectations. Bio-Techne addresses these\nchallenges through high-quality GMP materials, scalable manufacturing\nsolutions, and analytical technologies designed to improve consistency and\naccelerate development timelines. Recent industry discussions have\nincreasingly highlighted manufacturing scalability as a critical factor in\nenabling broader patient access to advanced therapies, reinforcing the\nimportance of investments such as the Bristol expansion.\n\n\"The opening of our Bristol facility represents more than additional\nmanufacturing capacity,\" said Will Geist, President of Bio-Techne's Protein\nSciences Segment. \"It strengthens Bio-Techne's ability to serve as a long-term\npartner for cell therapy innovators by providing the quality, scale, and\nglobal support necessary to navigate the journey from discovery to commercial\nsupply.\"\n\nThe Bristol facility is fully operational and is manufacturing GMP-grade small\nmolecules that support customers developing next-generation cell therapies\nworldwide.\n\nABOUT BIO-TECHNE\n\nBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company\nheadquartered in Minnesota, celebrating 50 years of empowering scientific and\ndiagnostic communities to reach better answers. The company provides\nhigh-quality reagents, analytical instruments, and precision diagnostics. Its\nportfolio is organized into three customer-focused brands: R&D Systems™,\nBio-Techne Spatial™, and Bio-Techne Diagnostics™, reflecting the\nscientific journey from discovery to translational research to clinical\ndecision-making. Bio-Techne operates in 34 locations worldwide and employs\nmore than 3,000 people. In fiscal year 2025, the company generated over $1.2\nbillion in net sales. Its more than 500,000 products are used globally by\nacademic researchers, biopharmaceutical and biotechnology companies, and\nclinical diagnostic laboratories.\n\nFor more information on Bio-Techne and its brands, please visit\nwww.bio-techne.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4789723-1&h=3730381129&u=https%3A%2F%2Fwww.bio-techne.com%2F&a=www.bio-techne.com)\n or follow the company on LinkedIn, X, or YouTube.\n\nMEDIA CONTACTS\n\nCorporate Communications\nmedia.relations@bio-techne.com (mailto:media.relations@bio-techne.com)\n\nDavid Clair, Vice President\nInvestor Relations\nIR@bio-techne.com (mailto:IR@bio-techne.com)\n\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/bio-techne-expands-global-gmp-manufacturing-network-with-new-bristol-facility-to-advance-scalable-cell-therapy-development-302900052.html\n(https://www.prnewswire.com/news-releases/bio-techne-expands-global-gmp-manufacturing-network-with-new-bristol-facility-to-advance-scalable-cell-therapy-development-302900052.html)\n\nSOURCE Bio-Techne Corporation\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS402613/Bio-Techne-Logo.jpg?id=OA2987796\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-08T12:00:07.912526084Z","server_sent_at_ms":1791460807912},"received_at":"2026-10-08T12:00:07.964Z","source_url":"https://www.prnewswire.com/news-releases/bio-techne-expands-global-gmp-manufacturing-network-with-new-bristol-facility-to-advance-scalable-cell-therapy-development-302900052.html"},"analysis":null,"durationMs":null,"modelName":null}}